Interferon alfa-2a drug interactions: Difference between revisions
(Created page with "__NOTOC__ {{Interferon alfa-2a}} {{CMG}} ==Drug Interactions== Roferon-A has been reported to reduce the clearance of theophylline.10,11 The clinical relevance of this intera...") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 10: | Line 10: | ||
Alpha-interferons may affect the oxidative metabolic process by reducing the activity of hepatic microsomal cytochrome enzymes in the P450 group. Although the clinical relevance is still unclear, this should be taken into account when prescribing concomitant therapy with drugs metabolized by this route. | Alpha-interferons may affect the oxidative metabolic process by reducing the activity of hepatic microsomal cytochrome enzymes in the P450 group. Although the clinical relevance is still unclear, this should be taken into account when prescribing concomitant therapy with drugs metabolized by this route. | ||
The neurotoxic, hematotoxic or cardiotoxic effects of previously or concurrently administered drugs may be increased by interferons. Interactions could occur following concurrent administration of centrally acting drugs. Use of Roferon-A in conjunction with interleukin-2 may potentiate risks of renal failure.<ref>{{Cite web | last = | first =|title = | The neurotoxic, hematotoxic or cardiotoxic effects of previously or concurrently administered drugs may be increased by interferons. Interactions could occur following concurrent administration of centrally acting drugs. Use of Roferon-A in conjunction with interleukin-2 may potentiate risks of renal failure.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ROFERON-A (INTERFERON ALFA-2A) INJECTION, SOLUTION [ROCHE PHARMACEUTICALS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c918b02-f158-4f7c-8ecc-fd49574ec228#nlm34090-1 | publisher = | date = | accessdate = 9 January 2014 }}</ref> | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Latest revision as of 14:03, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Drug Interactions
Roferon-A has been reported to reduce the clearance of theophylline.10,11 The clinical relevance of this interaction is presently unknown. Caution should be exercised when administering Roferon-A in combination with other potentially myelosuppressive agents. Synergistic toxicity has been observed when Roferon-A is administered in combination with zidovudine (AZT) (see WARNINGS: Bone Marrow Toxicity).
In transplant recipients, therapeutic immunosuppression may be weakened because interferons also exert an immunostimulatory action.
Alpha-interferons may affect the oxidative metabolic process by reducing the activity of hepatic microsomal cytochrome enzymes in the P450 group. Although the clinical relevance is still unclear, this should be taken into account when prescribing concomitant therapy with drugs metabolized by this route.
The neurotoxic, hematotoxic or cardiotoxic effects of previously or concurrently administered drugs may be increased by interferons. Interactions could occur following concurrent administration of centrally acting drugs. Use of Roferon-A in conjunction with interleukin-2 may potentiate risks of renal failure.[1]
References
- ↑ "ROFERON-A (INTERFERON ALFA-2A) INJECTION, SOLUTION [ROCHE PHARMACEUTICALS]". Retrieved 9 January 2014.
Adapted from the FDA Package Insert.